IceCure Medical Ltd. Overview
Pro stress-test →IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems designed to destroy benign and cancerous tumors by freezing them as a minimally invasive option to surgical tumor removal. The company's primary focus areas include breast, kidney, bone, and lung cancer, and its technology is intended to be performed in relatively short procedures.
Strategic Profile
Pro stress-test →The company's flagship product is the ProSense® Cryoablation System, described as a minimally invasive cryosurgical tool that uses liquid nitrogen to create large lethal zones for tumor destruction. The commercial-stage company markets its systems and technologies internationally, with presence in the United States, Japan, India, China, Israel, and other markets.
Competitive Landscape
Pro stress-test →Investors comparing IceCure often look at related companies in the medical devices sector, including Pulmonx Corp (LUNG), Volitionrx (VNRX), Baird Medical (BDMD), Apyx Medical Corporation (APYX), and Tela Bio, Inc. (TELA). IceCure's cryoablation technology positions it as a niche player in minimally invasive tumor treatment, competing against both traditional surgical approaches and alternative ablation technologies.
Industry Context
IceCure Medical Ltd. operates in Medical Devices.
Key facts
Founded: 2006 · Headquarters: Caesarea, Israel · Employees: N/A · Revenue: N/A · Market cap: $50.3M